Tulu Health Is Now in the US. Here's Why — and What's Next.

Tulu Health has officially arrived in the United States. And with every new market, the right people matter more than the product.

We started building Tulu Health in India — a market where healthcare complexity is measured not in millions of patients but in billions. Fragmented systems, variable payer landscapes, seven-plus spoken languages in a single catchment area, and clinical workflows built on decades of institutional memory. It is not an easy market to build AI for. That's exactly why we started there.

The lessons from India — around earning trust, integrating without disrupting, and proving ROI on a tight timeline — turned out to travel well. We took them to the UAE, then to Southeast Asia. At each new market, the surface-level challenges looked different. But the underlying problem was the same: longevity clinics and medspas are losing members they don't know they're losing, quietly, at scale, every day.

Why the US, Why Now

The US longevity and medspa market is growing faster than the operating layer underneath it. Membership churn runs 15-20% a year at most practices. Missed follow-ups and lapsed patients are the single biggest quiet drag on clinic revenue — quieter than a bad marketing quarter, but larger over time.

The tools that exist today — legacy EHRs, generic CRMs bolted on after the fact, standalone booking apps — were not built for the scale or complexity of what a growing membership-based practice faces. They patch individual problems. They don't connect the full patient relationship from first inquiry to lifetime membership.

That's what we've built. And after 50+ longevity clinics and medspas across three continents, we have the evidence base to show it works.

The People Matter More Than the Product

I've said this to our team many times, and it's as true now as when we started: entering a new healthcare market is not a product problem. It's a trust problem. You cannot deploy AI inside a clinic without people who understand the clinical, operational, and regulatory context of that specific market.

That's why, as we enter the US, we're leaning on the same physician-led approach we've built the company around from day one. Dr. Sanjiv Chopra, Faculty Dean for Continuing Medical Education at Harvard Medical School, has been part of how we think about clinical governance since the beginning — and that board-certified oversight extends to every new market we enter, including this one.

That combination of clinical depth and operating experience is rare, and it's exactly what's needed to ensure that what we build in the US doesn't just technically function — it actually gets adopted by the staff using it every day.

Every new market is a new chance to prove that the right AI, in the right hands, changes what's possible for patients.

What We're Building in the US

Our focus in the US market mirrors our global approach: four AI services built on one continuously updated Patient Twin, targeting the four biggest sources of lost revenue in a membership-based practice.

• AI Recall — Bring back patients who've gone quiet, at scale, in the channel and language they actually respond to.
• AI Front Desk — Answer, qualify, and book every inbound call or message, 24/7, no voicemail.
• AI Care Navigator — Keep every patient moving through their clinician-approved plan: follow-ups, tests, and adherence.
• AI Benchmarks (coming soon) — See how your practice performs against comparable clinics.

All four services read from and write back to a single Patient Twin, connect to your existing EHR and CRM, and can be deployed in sequence — starting with whatever is costing your practice the most right now.

We're currently onboarding our first US longevity clinics and medspas. If you're a practice owner or clinical director interested in seeing what this looks like for your patients, I'd like to talk.